Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gulley Website

James L. Gulley, M.D., Ph.D.

Portait Photo of James Gulley
Genitourinary Malignancies Branch
Branch Chief
Center for Cancer Research
National Cancer Institute
Building 10, Room 12N226
Bethesda, MD 20892-1750
Phone:  
301-435-2956
Fax:  
301-480-5094
E-Mail:  
gulleyj@mail.nih.gov

Gulley's Video Cast

Biography

Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a Ph.D. in microbiology in 1994 and an M.D. in 1995. As part of this eight-year M.D./Ph.D. Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI. Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 60 trials.

Dr. Gulley has received numerous awards, including the 2010 Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the U.S. government on outstanding scientists early in their careers. He serves on many national and NIH boards and committees. Dr. Gulley has authored more than 180 scientific papers and book chapters, edited 4 books and has made numerous invited presentations at national and international meetings.

Research

Dr. Gulley is especially interested in immunotherapy for prostate cancer. He works collaboratively with the Laboratory of Tumor Immunology and Biology, CCR, and takes promising laboratory findings and uses these to design and conduct clinical trials. These innovative, investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents to modulate the immune response in cancer patients, and the addition of other strategies to enhance vaccine-mediated killing. In particular, he played a pivotal role in the clinical development of a prostate cancer vaccine, created at the NCI, and he now serves as the Principal Investigator on a global Phase III randomized clinical trial (Prospect) of this vaccine.

This page was last updated on 3/31/2014.